COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

被引：0
|
作者：
Woods, B. [1 ]
Thompson, J. [1 ]
Barcena, L. [1 ]
Liu, Y. [2 ]
Huang, H. [2 ]
Martinez, C. [3 ]
机构：
[1] Oxford Outcomes, Oxford, England
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Inst Hematol & Oncol, Barcelona, Spain
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1728
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A509 / A509
页数：1
相关论文
共 50 条
  • [11] Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat
    Gautam, Ashish
    Zhu, Yanyan
    Ma, Esprit
    Lee, Shih-Yuan
    Zagadailov, Erin
    Teasell, Jeremy
    Richhariya, Akshara
    Bonthapally, Vijayveer
    Huebner, Dirk
    LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 69 - 76
  • [12] COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN TAIWAN
    Zou, D.
    Kendall, R.
    Lin, Q.
    Huang, Y.
    Tieng, J.
    Tseng, J.
    Sajosi, P.
    VALUE IN HEALTH, 2016, 19 (07) : A888 - A888
  • [13] BRENTUXIMAB VEDOTIN IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: A UNITED KINGDOM AND GERMANY RETROSPECTIVE STUDY
    Broeckelmann, P. J.
    Zagadailov, E. A.
    Corman, S.
    Hagan, M.
    Chirikov, V.
    Johnson, C.
    Macahilig, C.
    Seal, B.
    Dalal, M. R.
    Illidge, T.
    HAEMATOLOGICA, 2016, 101 : 50 - 51
  • [14] Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study
    Broeckelmann, Paul J.
    Zagadailov, Erin A.
    Corman, Shelby L.
    Chirikov, Viktor
    Johnson, Courtney
    Macahilig, Cynthia
    Seal, Brian
    Dalal, Mehul R.
    Illidge, Tim
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (06) : 553 - 558
  • [15] Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Rosenzweig, Jaclyn
    Mauguen, Audrey
    Buhtoiarov, Ilia
    Cuglievan, Branko
    Dave, Hema
    Deyell, Rebecca J.
    Flerlage, Jamie E.
    Franklin, Anna K.
    Krajewski, Jennifer
    Leger, Kasey J.
    Marks, Lianna J.
    Norris, Robin E.
    Pacheco, Martha
    Willen, Faye
    Yan, Adam Paul
    Harker-Murray, Paul D.
    Giulino-Roth, Lisa
    BLOOD ADVANCES, 2023, 7 (13) : 3225 - 3231
  • [16] Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
    Carmen Martínez
    Manuel Espeso de Haro
    Samuel Romero
    Antonio Gutiérrez
    Eva Domingo-Domènech
    Ana P. González-Rodríguez
    Izaskun Zeberio
    María Paz Martínez-Badas
    Antonia Rodríguez-Izquierdo
    Cecilia Carpio
    Mariana Bastos-Oreiro
    José Ángel Hernández-Rivas
    Rolando Vallansot
    Nicholas Kelleher
    Francisco J. Díaz-Gálvez
    Tamara Torrado
    Arturo Pereira
    Ramón García-Sanz
    Annals of Hematology, 2023, 102 : 429 - 437
  • [17] REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN (BV) VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RRHL) POST AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT)
    Zagadailov, E. A.
    Corman, S.
    Hagan, M.
    Chirikov, V.
    Johnson, C.
    Macahilig, C.
    Dalal, M. R.
    Broeckelmann, P. J.
    HAEMATOLOGICA, 2016, 101 : 98 - 99
  • [18] Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation
    Chung, Shanee
    White, Jennifer
    Toze, Cynthia L.
    Sutherland, Heather J.
    Sanford, David
    Rodrigo, Judith Anula
    Nevill, Thomas J.
    Narayanan, Sujaatha
    Nantel, Stephen H.
    Kuchenbauer, Florian
    Hay, Kevin A.
    Forrest, Donna L.
    Abou Mourad, Yasser
    Song, Kevin
    Power, Maryse
    BLOOD, 2021, 138
  • [19] BRENTUXIMAB VEDOTIN (BV) AN EFFECTIVE TREATMENT FOR TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)
    Viviani, S.
    Guidetti, A.
    Dalto, S.
    Dodero, A.
    Farina, L.
    Bolis, S.
    Rigacci, L.
    Zallio, F.
    Busca, A.
    Bruno, B.
    Mordini, N.
    Parvis, G.
    Corradini, P.
    HAEMATOLOGICA, 2015, 100 : 455 - 456
  • [20] Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
    Martinez, Carmen
    Espeso de Haro, Manuel
    Romero, Samuel
    Gutierrez, Antonio
    Domingo-Domenech, Eva
    Gonzalez-Rodriguez, Ana P.
    Zeberio, Izaskun
    Paz Martinez-Badas, Maria
    Rodriguez-Izquierdo, Antonia
    Carpio, Cecilia
    Bastos-Oreiro, Mariana
    Angel Hernandez-Rivas, Jose
    Vallansot, Rolando
    Kelleher, Nicholas
    Diaz-Galvez, Francisco J.
    Torrado, Tamara
    Pereira, Arturo
    Garcia-Sanz, Ramon
    ANNALS OF HEMATOLOGY, 2023, 102 (02) : 429 - 437
12345